Analyzing the Pharmacodynamic Substances and the Effects of Xingnaojing for Mild-to-Severe Acute Ischemic Stroke

• Status: Recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The main purposes of this trial are to analyze the pharmacodynamic substances and the effects of Xingnaojing for mild-to-severe acute ischemic stroke.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ying Gao
• Collaborator: Beijing Chaoyang Integrative Medicine Rescue and First Aid Hospital

Criteria

Inclusion Criteria:

• Diagnosis of Acute ischemic stroke；

• Symptom onset within 24 hours；

• 40 ≤ age ≤ 80 years;

• 4 ≤ NIHSS ≤ 25；

• Patient or legally authorized representative has signed informed consent.

Exclusion Criteria:

• Planned or already receiving intravenous thrombolysis or endovascular treatment;

• Suspected secondary stroke caused by tumor, brain trauma, or hematological diseases;

• Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scale score ≥ 2) ;

• Other conditions that cause cardiogenic embolism (e.g., atrial fibrillation, rheumatic heart disease, valvular heart disease);

• Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis);

• Significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) value that is twice the upper limit of normal);

• Life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer)

• Other conditions that render outcomes or follow-up unlikely to be assessed;

• Known to be pregnant or breastfeeding;

• Use any drugs containing traditional Chinese medicine within 1 week before enrollment;

• Currently receiving an investigational drug.